Rx Drug Pricing & Rebate Revised Fundamentals

American Conference Institute (ACI) organizes the 7th Annual Passport to Proficiency on Rx Drug Pricing & Rebate Revised Fundamentals. ACI is part of the C5 Group of Companies and produces conferences, events, and professional education programs for senior decision-makers.

This four-week virtual series provides intensive training in drug pricing, reimbursement, and rebate concepts across Medicaid, Medicare, PHS 340B, VA/FSS, and other key government payor programs. The 2026 program combines foundational instruction with advanced analysis of developments including Inflation Reduction Act (IRA) implementation, Medicare Drug Price Negotiation, PBM reform, state affordability initiatives, Most Favored Nation (MFN) pricing models, TrumpRx, direct distribution, and gross-to-net strategy.

The series will take place virtually from November 2 to December 2, 2026, during Eastern Standard Time. Sessions are scheduled twice each week on Mondays and Wednesdays across four weeks: November 2 and 4, November 9 and 11, November 16 and 18, and November 30 and December 2.

The program is designed for both emerging and experienced government pricing professionals, as well as legal, compliance, finance, contracting, reimbursement, managed markets, government affairs, market access, and commercial professionals. Relevant titles include corporate and general counsel, vice presidents, directors, managers, pricing and rebate specialists, financial analysts, compliance officers, and professionals responsible for Medicaid, Medicare, pharmacy networks, contracts, and reimbursement.

The audience typically includes pharmaceutical and biotechnology companies, law firms, pharmacies, pharmacy benefit managers, health plans, government agencies, consulting organizations, and other healthcare organizations. The program is especially relevant to teams working across drug pricing, market access, reimbursement, legal, compliance, finance, and government programs.

Topics include WAC and AWP, the Medicaid Drug Rebate Program, Best Price, AMP, URA and CPI-U, state drug price transparency laws, Prescription Drug Affordability Boards, PHS 340B, VA/FSS contracting, Federal Ceiling Price, Medicare Parts B and D, ASP, Medicare Drug Price Negotiation and Maximum Fair Price, inflation rebates, PBM reform, Most Favored Nation (MFN) models, launch pricing, biosimilars, direct-to-consumer and direct-to-employer models, TrumpRx, and gross-to-net performance.

Attendees will learn how drug prices are established, how rebate systems work, and how key pricing terms and methodologies apply across Medicaid, Medicare, PHS 340B, VA/FSS, and related government programs. The program also examines how to evaluate pricing, reimbursement, contracting, commercialization, and launch strategies while managing changing regulatory, affordability, market access, and gross-to-net considerations.

The speaker faculty includes in-house counsel, government pricing and reimbursement executives, market access leaders, law firm partners and counsel, consultants, and government officials with experience in pharmaceutical pricing and reimbursement. The 2026 agenda also includes specialists in 340B, Medicaid, Medicare, VA/FSS contracting, PBM reform, launch strategy, and gross-to-net planning.

Organizations represented on the confirmed 2026 faculty include the Centers for Medicare & Medicaid Services (CMS), Maryland Prescription Drug Affordability Board, UCB, Gilead Sciences, Sanofi, Teva Pharmaceutical, Jazz Pharmaceuticals, Woven, Blank Rome LLP, Sidley Austin, Covington & Burling, Goodwin Procter, K&L Gates, DLA Piper, Manatt, ArentFox Schiff, Polsinelli, Reed Smith, Gibson Dunn, Holland & Knight, and Latham & Watkins. The faculty brings together government, in-house, legal, consulting, and market access perspectives.

The virtual Proficiency Series is designed to encourage dialogue with faculty and fellow attendees through the interactive chat, giving participants opportunities to exchange ideas, compare approaches, and build a professional peer network. Two interactive LAB (Learn, Apply, and Benchmark) sessions add hands-on learning and direct engagement around the FSS application process and pricing and rebate exercises across Medicaid, Medicare, and 340B.

Yes. Groups of 4-8 attendees from the same organization receive a 10% discount, while groups of 9-12 receive a 15% discount. Groups of more than 12 should contact ACI for available rates; team members must be from the same organization or firm and register together in one transaction.

Registrants who register and pay are eligible for a full refund until October 23, 2026. If unable to attend, registrants may request either a full refund or a full credit note for themselves or a colleague to attend another event; all cancellations and changes must be submitted to ACI’s Customer Experience Team by October 23.

CLE and CPE credits are available for the Proficiency Series. Credit eligibility and requirements may vary by jurisdiction or professional body. Learn more about CPE on our CPE Accreditation Page or reach out to our Continuing Education team at [email protected] with your specific inquiry.